申请人:Eli Lilly and Company
公开号:US07705025B2
公开(公告)日:2010-04-27
The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
本发明提供了一种新的化合物,其化学式为(I),或其药学上可接受的盐,具有组胺H3受体拮抗剂或反向激动剂活性,并提供了制备这种化合物的方法。在另一个实施例中,本发明还揭示了包括化合物(I)的制药组合物以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。